- $156.05m
- $102.51m
- $42.17m
Coherus BioSciences Inc reports results for the quarter ended in January - Earnings Summary
Brief: Coherus BioSciences Q2 EPS USD -0.11
Coherus BioSciences Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Coherus BioSciences Says Entered Into Exclusive License And Distribution Agreement With Apotex
U.S. RESEARCH ROUNDUP-AT&T, ATI, California Resources
Brief: Coherus Biosciences Announces Divestiture Of YUSIMRY (Adalimumab-Aqvh) In A $40 Mln Upfront All Cash Transaction
Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars
Brief: Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Brief: Coherus Presents Preliminary Results From Phase I Dose Escalation Study Of Its Anti-Chemokine Receptor 8 Antibody
U.S. RESEARCH ROUNDUP- AMC Networks, Permian Resources, Vital Energy
Coherus BioSciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Coherus BioSciences Q1 EPS USD 0.83
Brief: Coherus Announces Full Repayment Of Pharmakon Advisors $75 Million Term Loan
Brief: Coherus To Collaborate With The Cancer Research Institute
Coherus BioSciences Inc expected to post a loss of 24 cents a share - Earnings Preview
Coherus BioSciences Inc expected to post a loss of 24 cents a share - Earnings Preview
Coherus BioSciences Inc reports results for the quarter ended in December - Earnings Summary
Coherus falls after Q4 revenue misses estimates
Brief: Coherus BioSciences Q4 EPS USD -0.71